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Abstract
This paper by John D. Keen and James E. Keen addresses a thorny subject. The numerical findings
and commentaries in their paper will be disturbing to some readers and seem to defy logic and well
established viewpoints. It may well generate angry letters to the editor. However such numerical
analysis and reporting including civil discussion should be welcomed and are the basis for informed
decision making – something that is highly needed in this field.
Keen and Keen find that, depending on the particular
population subset, of the order of a thousand persons
need to be screened for early detection of breast cancer in
order to save one additional life [1]. The remainder who
do not benefit from early detection can have side effects of
which they name anxiety, loss of time, unnecessary proce-
dures, and radiation. The numbers are somewhat worse
for younger women. They also comment and imply that
early detection of cancer is a business with a large market
and we should keep that in mind when we read papers
and when women are urged to have mammographic
screening to improve the mortality and morbidity from
breast cancer. As Keen and Keen note, benefits are often
exaggerated and side effects are often minimized.
I have studied this field for a number of years from a far
distant vantage point. My opinions in this subject are
mostly in agreement with Keen and Keen. That is, their
comments and numerical results are consistent with my
knowledge and experience. However, the situation is far
more scientifically complex and politically charged than
as they describe. I hope readers will become interested in
this fascinating subject and study the literature. Early
detection of breast cancer is scientifically most interesting
but unfortunately this is often lost in the arguing that has
taken place.
Consider that we had a cancer paradigm consisting of
detection of cancer by no special means and subsequent
treatment by surgery and possible adjuvant therapy. Now
we perturb or probe the system by introducing routine
early detection. Do the new results on outcome agree with
our expectations? If they do, then we gain confidence that
we understand the disease and how it progresses. If they
do not, then perhaps our understanding of the disease
process was faulty and needs to be reconsidered. Such
experimental opportunities are rare in cancer care so we
need to fully exploit the scientific situation.
It has long been known that the probability of cure with
just surgical removal of the primary tumor after diagnosis
of breast cancer is highest for patients with the smallest
primary tumors and no invasion of the axillary lymph
nodes. The probability of cure decreases as the tumor size
and the number of lymph nodes with cancer cells
increases. It was eminently logical that early detection
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would be a benefit. Trials to determine the quantitative
value of detecting cancer early began in the 1960s and still
continue.
When they evaluated benefit of early detection of cancer
for women age 50–59, there was an early appearing and
strong 20 – 30% mortality advantage to early detection.
This was expected. However, when they did the same
thing for women age 40–49, there was an unexpected
early mortality disadvantage to mammography that later
became the anticipated advantage after 6 or more years.
Essentially equivalent results were reported from a
number of trials that occurred in different countries and
over several decades of time.
This was not what people wanted to hear. When disputed
and clinically important results occur, NIH often holds a
consensus conference where all data are presented and an
expert panel reviews data and makes recommendations.
The majority of scientists who examined the trial data
concluded there is no evidence supporting the use of
mammography for women age 40–49. A vocal minority
disagreed.
Since the trials of early detection of breast cancer encom-
pass the entire cancer process from recruitment of suppos-
edly healthy individuals, ensuing treatment, to long term
survival or death presumably due to cancer, there are
many opportunities for biases or potential biases to
appear. It was easy to criticize the trials for actual or pos-
sible biases. By discarding these data, they were then free
to make decisions based on their biases. Screening advo-
cates concluded that routine mammography should be
started at age 40 since, despite trial data, they were sure
early detection is beneficial. The Director of the NIH as
well as the US Senate (by a vote of 98 to 0) decided that
the trials were wrong and mammography should start at
age 40. For a colorful report of that NIH consensus confer-
ence, see the New England Journal of Medicine paper by
Suzanne Fletcher in which the consensus conference is
compared to Alice in Wonderland [2].
A number of years ago, based on a study of bimodal
relapse patterns in clinical data, my colleagues and I pro-
posed that breast cancer growth includes periods of quasi-
stable dormancy and that surgery to remove the primary
tumor can kick-start growth of dormant distant single
malignant cells and micrometastases. According to our
report, this is very common in that over half of all relapses
in breast cancer are accelerated by such mechanisms. For
premenopausal women with positive lymph nodes, there
is a particularly high incidence of surgery-induced angio-
genesis that results in very early relapses. These effects
would reduce the benefit of early detection in the short
term but not affect the long term benefit. For premeno-
pausal women there would be a particularly sharp early
effect. We calculated that based on clinical data, 0.1/1000
young women screened would relapse and die 2–3 years
after the start of screening. This quantitatively explained
the excess mortality for trials to test the benefit of early
detection of breast cancer for women age 40–49. The the-
ory also at least partly explained why there is only modest
benefit of early detection of breast cancer in general [3].
In the trials, some apparently healthy young women died
from breast cancer 3 years after mammography began. As
frequently happens in this subject, the numbers are very
small despite many women screened. According to a
meta-analysis, there might barely be a statistically signifi-
cant excess mortality at 3 years for young women. The dis-
turbing implication is that most people derive benefit
from early detection however other people especially
young women may die earlier as a result of early detec-
tion. It must be emphasized that modern adjuvant ther-
apy moderates these early events to some degree.
There is also the possibility that the extra biopsies result-
ing from extra imaging studies could produce extra
patients with more positive lymph nodes as another pos-
sible side effect of routine mammography [4].
Our papers on this subject generated several news reports.
In one major web report, the director of screening for
American Cancer Society (ACS) is quoted as saying read-
ers should not believe any of this [5,6]. ACS provides a
very valuable service to the community but we might keep
in mind that this is a multi-billion dollar market and
allegedly there are historic ties to the mammography and
radiology communities [7].
One of our papers on early detection generated an angry
and insulting letter to the editor [8] by a noted mammog-
raphy advocate who has written similar letters before [9].
Such an environment is not helpful for unbiased scientific
research.
Of course there are many knowledgeable and well-mean-
ing advocates who will disagree with the findings of Keen
and Keen. However, as one recent very negative report pre-
senting data along the lines of the Keen and Keen find-
ings, Gotzsche et al [10] note that "If 2000 women are
screened regularly for 10 years, one (additional person)
will benefit from the screening, as she will avoid dying
from breast cancer. At the same time, 10 healthy women
will, as a consequence, become 'cancer patients' and will
be treated unnecessarily."
We have all been told many times that mammography
saves lives. That is certainly true but it also may result in
other things that are not beneficial and we need a decisionPublish with BioMed Central    and   every 
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algorithm that includes more of these effects. The study by
Keen and Keen is a positive step in the right direction. As
Dr. Cornelia Baines (co- PI of a large trial of early detec-
tion for women age 40–49) writes, women age 40–49 are
asked to sign informed consent for mammography with-
out being properly informed [11].
Competing interests
I occasionally consult in lawsuits involving delayed diag-
nosis of cancer. I also have submitted a patent application
for a therapy for early stage breast cancer that does not
produce surgery-induced metastatic growth [12]. I am a
founder and on the Board of Directors of the Colon Can-
cer Alliance [13] for which I receive no compensation.
Early detection of colon cancer has its own set of prob-
lems but it seems that dormancy and surgery-induced
metastatic growth are at most small effects in early stage
colon cancer compared to breast cancer. I think there
should be more effort to increase early detection of colon
cancer for men and women over age 50 and full informa-
tion should be provided to women regarding possible
serious side effects of early detection of breast cancer espe-
cially for women under age 50.
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